ReviewFuture oncology (London, England)2022

Tremelimumab and durvalumab in the treatment of unresectable, advanced hepatocellular carcinoma.

Tiago Biachi de Castria et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.